Abstract
Aim: Background: The ORION-1 trial demonstrated that inclisiran, an RNAi Therapeutic which targets PCSK9 messenger RNA within hepatocytes, produces significant reductions in LDL-C reduction while requiring fewer injections than PCSK9 monoclonal antibodies (mAbs). The effects of inclisiran on other lipids is less well described.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
